LGC Biosearch Technologies

LGC Biosearch Technologies, Inc., founded in 1993, is a key player in the Pharmaceuticals and Healthcare industries, specializing in the design and manufacture of nucleic acid-based products for genomic information discovery and application. The company offers a range of solutions including ValuPanel Reagents, Stellaris RNA FISH probes for mRNA detection and quantification, fluorogenic probes and primers, custom oligonucleotides, and DNA/RNA synthesis reagents. It also provides essential labeling reagents and immunochemicals, supporting advanced research and diagnostics. With a global presence indicated by its numerous hashtags and a subsidiary status under LGC Limited since 2015, LGC Biosearch Technologies serves a broad scientific community.

Operating with an employee range of 500 - 1,000 individuals across 16 locations, the company focuses on delivering mission-critical tools for life science research. Its product portfolio is designed to accelerate genomic insights, from basic research to applied genomics. The team's expertise is crucial in developing and supporting these advanced molecular biology tools, enabling scientists to achieve faster and more accurate results in their work. Meet LGC Biosearch Technologies's team to understand the expertise driving their innovation.

LGC Biosearch Technologies competes in a dynamic market alongside major entities such as Illumina, Abcam, and Oxford Nanopore Technologies. Its revenue stands at $28.7M, reflecting its significant contribution to the life sciences sector. The company's strategic focus on nucleic acid technologies positions it to support advancements in areas like personalized medicine, diagnostics, and synthetic biology, leveraging its established product lines and ongoing research and development efforts to meet evolving scientific demands.